诊断学理论与实践››2018,Vol. 17››Issue (02): 141-146.doi:10.16150/j.1671-2870.2018.02.004
娄加陶, 张宸梓
收稿日期:2018-03-21出版日期:2018-04-25发布日期:2018-04-25
Received:2018-03-21Online:2018-04-25Published:2018-04-25| [1] Tkach M, Théry C. Communication by extracellular vesicles: Where we are and where we need to go[J]. Cell,2016,164(6):1226-1232. [2] Zaborowski MP, Balaj L, Breakefield XO, et al. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study[J]. Bioscience,2015,65(8):783-797. [3] Raposo G, Nijman HW, Stoorvogel W,et al.B lymphocytes secrete antigen-presenting vesicles[J]. J Exp Med,1996, 183(3):1161-1172. [4] Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes[J]. Nat Med,1998, 4(5):594-600. [5] Théry C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids[J]. Curr Protoc Cell Biol,2006. [6] Stahl PD, Barbieri MA. Multivesicular bodies and multivesicular endosomes: the "ins and outs" of endosomal traffic[J]. Sci STKE,2002,2002(141):pe32. [7] Clayton A, Turkes A, Dewitt S, et al. Adhesion and signaling by B cell-derived exosomes: the role of integrins[J]. FASEB J,2004,18(9):977-999. [8] Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis[J]. Proc Natl Acad Sci U S A,2003,100(19):10592-10597. [9] Clayton A, Harris CL, Court J, et al. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59[J]. Eur J Immunol,2003,33(2):522-531. [10] Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming[J]. Nat Med,2001,7(3):297-303. [11] Chen TS, Lai RC, Lee MM, et al. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs[J]. Nucleic Acids Res,2010,38(1):215-224. [12] Beninson LA, Fleshner M. Exosomes: an emerging factor in stress-induced immunomodulation[J]. Semin Immunol,2014,26(5):394-401. [13] Carlsson L, Nilsson O, Larsson A, et al. Characteristics of human prostasomes isolated from three different sources[J]. Prostate,2003,54(4):322-330. [14] Chaput N, Flament C, Viaud S, et al. Dendritic cell derived-exosomes: biology and clinical implementations[J]. J Leukoc Biol,2006,80(3):471-478. [15] Théry C, Duban L, Segura E, et al. Indirect activation of na?ve CD4+ T cells by dendritic cell-derived exosomes[J]. Nat Immunol,2002,3(12): 1156-1162. [16] Munich S, Sobo-Vujanovic A, Buchser WJ, et al. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands[J]. Oncoimmunology,2012,1(7):1074-1083. [17] Romagnoli GG, Zelante BB, Toniolo PA, et al. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets[J]. Front Immunol,2014,5:692. [18] Klibi J, Niki T, Riedel A, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells[J]. Blood, 2009,113(9):1957-1966. [19] Liu ZM, Wang YB, Yuan XH. Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+ T cells[J]. Asian Pac J Cancer Prev, 2013,14(1):309-314. [20] Tominaga N, Kosaka N, Ono M, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier[J]. Nat Commun,2015,6:6716. [21] Felicetti F, De Feo A, Coscia C, et al. Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma[J]. J Transl Med,2016,14(1):56. [22] Altieri SL, Khan AN, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine[J]. J Immunother,2004,27(4): 282-288. [23] Cho JA, Yeo DJ, Son HY, et al. Exosomes: a new delive-ry system for tumor antigens in cancer immunotherapy[J]. Int J Cancer, 2005,114(4):613-622. [24] Hao S, Bai O, Yuan J, et al. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes[J]. Cell Mol Immunol, 2006,3(3):205-211. [25] Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1[J]. Nat Commun,2016,7:11150. [26] Cvjetkovic A, L?tvall J, L?sser C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles[J]. J Extracell Vesicles,2014,3. [27] Rani S, O'Brien K, Kelleher FC, et al. Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling[J]. Methods Mol Biol,2011,784:181-195. [28] Vickers KC, Palmisano BT, Shoucri BM, et al. Micro RNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins[J]. Nat Cell Biol,2011, 13(4):423-433. [29] Rider MA, Hurwitz SN, Meckes DG Jr. ExtraPEG: A polyethylene glycol-based method for enrichment of extracellular vesicles[J]. Sci Rep,2016,6:23978. [30] Maas SL, de Vrij J, van der Vlist EJ, et al. Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics[J]. J Control Release,2015,200:87-96. [31] Dragovic RA, Gardiner C, Brooks AS, et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis[J]. Nanomedicine,2011,7(6):780-788. [32] Wyss R, Grasso L, Wolf C, et al. Molecular and dimensional profiling of highly purified extracellular vesicles by fluorescence fluctuation spectroscopy[J]. Anal Chem,2014,86(15):7229-7233. [33] Gy?rgy B, Módos K, Pállinger E, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters[J]. Blood,2011,117(4):39-48. [34] Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends[J]. J Cell Biol,2013, 200(4):373-383. [35] Lai CP, Mardini O, Ericsson M, et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter[J]. ACS Nano,2014,8(1):483-494. [36] Sheridan C. Exosome cancer diagnostic reaches market[J]. Nat Biotechnol,2016,34(4):359-360. [37] Royo F, Zu?iga-Garcia P, Torrano V, et al. Transcripto-mic profiling of urine extracellular vesicles reveals alte-rations of CDH3 in prostate cancer[J]. Oncotarget,2016,7(6):6835-6846. [38] Zhang P, He M, Zeng Y, et al. Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured graphene oxide/polydopamine coating[J]. Lab Chip,2016, 16(16):3033-3042. [39] Hsu DH, Paz P, Villaflor G, et al. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides[J]. J Immunother,2003,26(5):440-450. [40] Morse MA, Garst J, Osada T, et al. A phase Ⅰ study of dexosome immunotherapy in patients with advanced non-small cell lung cancer[J]. J Transl Med,2005,3(1):9. [41] Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase Ⅰ clinical trial[J]. J Transl Med,2005,3(1):10. [42] Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis[J]. Cancer Res,2011,71(11):3792-3801. [43] Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway[J]. Nat Cell Biol,2010,12(1):19-30. [44] Thompson CA, Purushothaman A, Ramani VC, et al. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes[J]. J Biol Chem,2013,288(14):10093-10099. [45] Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells[J]. J Clin Invest, 2010,120(2):457-471. [46] Miyanishi M, Tada K, Koike M, et al. Identification of Tim4 as a phosphatidylserine receptor[J]. Nature, 2007, 450(7168):435-439. [47] Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells[J]. J Biol Chem,2009,284(49):34211-34222. [48] Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy[J]. J Cell Physiol,2012,227(2):658-667. [49] Kosaka N, Yoshioka Y, Tominaga N, et al. Dark side of the exosome: the role of the exosome in cancer metastasis and targeting the exosome as a strategy for cancer therapy[J]. Future Oncol,2014,10(4):671-681. |
| [1] | 倪瀚文, 吴立群.外泌体在心肌缺血及房颤诊治中的应用前景研究进展[J]. 诊断学理论与实践, 2020, 19(02): 199-202. |
| [2] | 朱巍巍, 万颖蕾, 刘锦燕, 张华, 陈华, 项明洁.内毒素的检测方法与临床应用进展[J]. 诊断学理论与实践, 2017, 16(06): 668-671. |
| [3] | 何沂峰, 王新文, 陈克敏,.肺实质含血量的异常改变及其测量方法的相关进展[J]. 诊断学理论与实践, 2013, 12(05): 564-566. |
| [4] | .互刊信息[J]. 诊断学理论与实践, 2009, 8(01): 110-. |
| [5] | 谢松业, 黄盛, 丁星, 张蕾,.一种简便直接半定量检测抗HEV-IgG的方法及其临床观察[J]. 诊断学理论与实践, 2008, 7(02): 202-205. |
| [6] | 孔晓飞,张欣欣,张申英,张东华,金根娣,陆志檬.干扰素信号传导相关蛋白和基因检测方法的初步建立和应用[J]. 诊断学理论与实践, 2004, 3(01): 16-20. |
| [7] | 陈楠.肾小球滤过功能检测方法的评估[J]. 诊断学理论与实践, 2003, 2(04): 9-11. |
| [8] | 苏长青.以端粒酶为靶点的肿瘤诊断与基因治疗策略[J]. 诊断学理论与实践, 2003, 2(03): 67-69. |
| [9] | 李家增.重视血栓与止血检测方法的合理选择[J]. 诊断学理论与实践, 2002, 1(02): 6-7. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
